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Background. Excessive prescription of antibiotics in patients with lower respiratory tract infec-
tion (LRTI) is common in primary care and might be reduced by rapid point-of-care (POC)
C-reactive protein (CRP) testing. However, the exact benefits of this test are unclear.
Objective. To review the available evidence for the role of POC CRP measurement in (i) guiding
antibiotic prescription, (ii) predicting aetiology, (iii) prognosis and (iv) diagnosis (pneumonia) in
LRTI patients.
Methods. For each research question, studies were retrieved through an electronic literature
search in Medline, Embase and the Cochrane Library using synonyms for CRP and LRTI combined
with different relevant subheadings. Study quality was assessed using validated instruments and
predefined outcome measures were extracted from each study.
Results. The search yielded 13 articles, each answering one or more questions; one was excluded
by insufficient internal validity. (i) One of four studies showed a significant reduction in the anti-
biotic prescriptions when applying POC CRP measurement [relative risk (RR) 0.6, 95% confidence
interval (CI) 0.5–0.7]. (ii) Three studies on aetiology demonstrated that an elevated CRP was asso-
ciated with bacterial [odds ratio (OR) 2.46–4.8] and one with viral (OR 2.7) aetiology. (iii) Results
on the prognostic value were contradictory, providing evidence for faster symptom resolution
(RR 1.16, 95% CI 1.1–1.3), higher mortality rate (RR 2.5, 95% CI 1.2–5.1) and no difference in outcome
in patients with high CRP levels. (iv) Four studies showed that CRP had limited value as a single
predictor of pneumonia. When combined with clinical assessment, its value increased according
to two of these studies (receiver operating characteristic area from 0.7 to 0.9). However,
methodological flaws and/or wide CIs limit the generalizability of findings in all studies.
Conclusion. The evidence for the benefits of POC CRP measurement in LRTI patients in primary
care is limited, contradictory and does not support its use to guide treatment decisions yet.
Keywords. Antibiotic prescription, aetiology, C-reactive protein, diagnosis, point-of-care,
primary care, prognosis.
Introduction
Excessive prescription of antibiotics in patients with
lower respiratory tract infection (LRTI) is a substantial
problem in Western Europe. In the Netherlands, inap-
propriate prescribing in LRTI is as high as 86%.1 Ex-
cessive use of antibiotics drives the development of
antimicrobial resistance, medicalization of patients
and increases health care costs.2,3
Point-of-care (POC) C-reactive protein (CRP) mea-
surement may reduce diagnostic uncertainty, conse-
quently unnecessary antibiotic prescription and even
increase patients’ adherence to therapy.4,5 It is a rapid
quantitative test which can be performed at the GP’s
office and requires a droplet of blood obtained by fin-
ger prick. Results are available within 2 minutes. Most
POC analyzers detect CRP levels between 5 and 200
mg/l with a level of <20 mg/l indicating a healthy
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patient or non-severe infection. Average purchasing
costs are e1837—with an additional of e4—per test.6–8
Recently issued Dutch guidelines, serving as a proto-
col for GPs, advocate the use of POC CRP testing in
LRTI patients at intermediate risk of severe infec-
tion,9 while the diagnostic value of this test in (these)
LRTI patients can be questioned. For example, a sys-
tematic review, including hospitalized patients and
children, showed that CRP measurement was insuffi-
ciently sensitive and specific to act as a diagnostic tool
to predict bacterial aetiology or radiographic pneumo-
nia.10 It is unknown to what extent these results are
applicable to an adult primary care population, with
a different pretest probability.
Strikingly, implementation of POC CRP testing in
Scandinavian countries resulted in excessive use of
the test and continuous suboptimal use of antibiotics
in primary care.11,12 An observation of routine prac-
tice showed that the POC CRP level does influence
antibiotic prescribing, but the use of POC CRP testing
in itself does not substantially reduce the overall
amount of antibiotic prescriptions [relative risk (RR)
1.1].2 These observations urge (Dutch) professionals
to be critical when implementing POC CRP measure-
ment in daily practice on a large scale. We will there-
fore review the available evidence for the effect of
POC CRP measurement on the management of adult
patients with suspected LRTI presenting in primary
care and the rationale behind CRP measurement in
these patients. We will focus on (i) prescription of
antibiotics, (ii) prediction of aetiology, (iii) prognosis
and (iv) diagnosis (i.e. pneumonia).
Methods
Search strategy
An electronic literature search by title and abstract
was performed in Medline, Embase and the Cochrane
Library, from January 1975 to July 2010. The search
was limited to published studies only. Search terms
and medical subheadings differed per research ques-
tion (Table A1). No methodological filters were ap-
plied and no articles were excluded by language. The
search was supplemented by screening of related ar-
ticles, references and citations of relevant studies and
(inter-) national guidelines on LRTI. Authors and/or
publicists were contacted when the full text version
was not available.
Study selection and data extraction
Based on title and abstract, two authors (MFE and
FPP) independently selected full text articles based
on predefined inclusion and exclusion criteria. These
inclusion and exclusion criteria were the same for all
the four research questions. Studies using adult pa-
tients (>16 years of age) consulting their GP with
a probable LRTI were included if CRP was measured
in (a part) of those patients. ‘Probable LRTI’ had to
be defined as the presence of clinical criteria suggest-
ing LRTI or a diagnosis of LRTI made by the physi-
cian, small differences in definitions of LRTI between
studies were accepted.
Exclusion criteria were letters, editorials, reviews
and single case reports. Studies that only described up-
per respiratory infections, patients with confirmed
pneumonia or bronchitis and/or immunocompromised
patients (HIV) were also excluded. Studies describing
hospitalized patients or patients presented on the
emergency department were excluded, as a hospital-
based population consists of more severely ill patients
and would produce a higher pretest probability of an-
tibiotic prescriptions, (bacterial) pneumonia and poor
prognosis. In studies on diagnosis, for example, this
would lead to an overestimation of the discriminatory
value of CRP in all LRTI patients.13,14 Studies not
presenting data for LRTI patients in primary care sep-
arately were excluded as well. In addition, specific in-
clusion and exclusion criteria were formulated to
match each different research question as follows.
Antibiotic prescription. Studies that evaluated the ef-
fect of CRP measurement on antibiotic prescription
were only included if a POC CRP test was used in
a study setting (i.e. excluding cohort studies describing
daily practice). Studies needed to provide a RR or
quantitative information from which a RR could be
extracted.
Aetiology. Aetiologic studies had to provide the neg-
ative (NPV) and positive predictive value (PPV) of
CRP measurement compared to a reference test con-
sisting of sputum cultures, throat swabs and/or serol-
ogy. Because aetiologic testing in the general
population is not feasible, the prevalence of bacterial
colonization in the community is unknown, the preva-
lence in LRTI patients presenting in primary care is
380 per 1000 LRTI patients.15
Prognosis. To determine the prognostic value of
CRP we included articles providing the RR, or data
from which it could be calculated, of persisting symp-
toms and/or mortality for different CRP cut-off points.
Diagnosis. Studies that evaluated the diagnostic prop-
erties of CRP were only included if chest radiography
was used as a reference test; international guidelines
define community-acquired pneumonia (CAP) as clini-
cal symptoms suggestive for LRTI combined with ra-
diographic findings suggestive for CAP.16,17 The NPV
and PPV of CRP measurement had to be provided. The
reported prevalence of CAP in the community ranges
from 8 to 12 per 1000 inhabitants,18,19 the incidence in











LRTI patients ranges from 60 per 1000 overall to 130
per 1000 in winter seasons.15,20,21
Per article, one of two authors (MFE and FPP) ex-
tracted all relevant data and the second author verified
if the retrieved data matched the original article. Be-
fore comparison of the aforementioned outcome
measures, relevant study data were retrieved and com-
pared. These data included design (including randomi-
zation and blinding); inclusion and exclusion criteria;
selection procedures; demographic data, co-morbidity
and signs and symptoms of participants; performance
of CRP measurement and reference tests (setting and
timing); follow-up and statistical analysis methods. CRP
cut-off values were displayed as described in the original
studies. Authors were contacted if the original data were
required for comparison, data were not reanalysed.
Quality assessment
Study quality was independently evaluated by two au-
thors (MFE and FPP). To assess study quality and
identify sources of bias, the QUADAS (Quality As-
sessment of Studies of Diagnostic Accuracy) was used
for diagnostic studies and the Cochrane validity score
was used for randomized controlled trials (RCTs) and
the remaining cohort studies.22,23 A score was calcu-
lated by dividing the amount of items the study was
scored on by the amount of positive results (Supple-
mentary Table 1, see online supplementary material).
This resulted in a percentage which was labelled ‘val-
idity score’. Studies with a low validity score (<50%)
were excluded from this review. The initial agreement
between authors was evaluated and Cohen’s Kappa
was calculated. Disagreements were solved after dis-
cussion with the entire study group.
Results
After applying the inclusion and exclusion criteria,
13 articles originating from 10 studies were retrieved.
Each article answered one or more research questions.
Five articles discussed antibiotic prescription, four aeti-
ology, three prognosis and three diagnosis. Figure 1 il-
lustrates the flow of articles through the review
process. Two articles were derived from the same study
20,24 and all three articles by Hopstaken et al. are suba-
nalyses derived from data from one RCT described
elsewhere.21,25–27
Quality assessment
Table 1 shows the results of the assessment of rele-
vance and quality. Initial agreement between the two
quality assessors was 97% (j = 0.97). Overall quality
of the included studies varied from low to excellent.
One study on antibiotic prescription had a low internal
validity (validity score 17%); the appraisal revealed
major methodological flaws (Supplementary Table 1,
see online supplementary material), it was therefore
excluded from this review.28
Study characteristics
Table 2 lists the main characteristics of the 12 retrieved
articles derived from 9 original studies. All studies dis-
cussed LRTI only or displayed results for LRTI sepa-
rately from other conditions. One paper discussed both
adults and children; data on adults only were retrieved
by contacting the author.29 The relevant outcome meas-
ures were provided in all retrieved articles.
Synthesis of results
Details of study results are listed in Table 2, subdivided
by research question.
Can rapid POC CRP measurement in primary care
reduce antibiotic prescription? Comparison of study
populations of the four studies on this subject shows
comparable duration of symptoms and frequencies of
fever. The incidence of cough in these groups, how-
ever, varies from 40% to 100%. Overall, the RR of an
antibiotic prescription at index consultation ranged
from 0.58 to 0.96 in the POC CRP group compared
to the control group.4,29–31 One study, with the lowest
validity score (56%), showed that prescribing antibiot-
ics based on the results of rapid POC CRP measure-
ment can reduce the amount of antibiotic prescriptions
significantly. A difference between the POC CRP and
the control group was found [RR 0.58, 95% confidence
interval (CI) 0.5–0.7], remaining significant after 28 days
of follow-up (RR 0.77, 95% CI 0.6–0.9). However, con-
trols had abnormalities on chest auscultation more of-
ten than cases, which might have influenced antibiotic
prescription.31 Patient’s outcome was comparable for
the intervention and control group in this study, sug-
gesting that the withholding of antibiotics did not com-
promise patient outcome. Concordantly, two additional
studies showed no significant difference in patient out-
come.4,30 Diederichsen et al.,29 however, showed that
patients in the CRP group had a slightly longer dura-
tion of symptoms compared to the control group.
Can CRP levels identify bacterial aetiology in
LRTI? Different patient characteristics were de-
scribed in each study restricting the comparability of
study populations. The population in the study by
Melbye et al.,30 for example, shows significantly less
fever and cough and a shorter duration of symptoms
as compared to the remaining study populations. High
CRP values, measured in the laboratory, were gener-
ally associated with a confirmed aetiological diagnosis
in all four studies. One author identified an association
between an elevated CRP (>50 mg/L) and viral aeti-
ology [odds ratio (OR) 2.7, 95% CI 1.4–5.2]. However,
this association was only observed when comparing pa-
tients with viral LRTI to patients with microbiologically











unexplained LRTI and may have been due to the fact
that patients with microbiologically unexplained LRTI
were less ill and therefore less likely to show strong
acute-phase responses.25
Holm et al.24 showed contrasting results; an elevated
CRP (>20 mg/L) was associated with bacterial aetiol-
ogy (OR 2.58, 95% CI 1.51–4.43) compared to all
other causes of LRTI. Furthermore, Macfarlane et al.
compared a group of patients with bacterial and atypi-
cal LRTI to a group with viral and unexplained LRTI,
using a CRP cut-off value of >50 mg/l. The OR for
CRP predicting bacterial/atypical LRTI was 2.46
(95% CI 1.3–4.6).15 The study by Graffelman et al.
also showed an association between bacterial LRTI
and high CRP levels compared to viral LRTI. CRP
cut-off values of >20 and >50 mg/l yielded ORs of 4.8
(95% CI 1.3–18) and 2.6 (95% CI 1.0–6.5), respec-
tively. In the multivariate analysis, CRP did not have
additional value to history and physical examination
alone in predicting bacterial aetiology of LRTI.32
Does CRP level in LRTI patients have prognostic
value? Study populations of the three retrieved stud-
ies differ greatly, for example, the population used by
Seppa et al. consisted of mainly elderly patients. There
was a wide variety between groups in incidence of
cough, fever, abnormalities on chest auscultation and
duration of symptoms. One study showed that CRP,
measured in the laboratory, was not a significant pre-
dictor of symptom resolution.26 Strikingly, a study by
Melbye et al. showed that a CRP level of >11 mg/l was
associated with a shorter duration of illness (calculated
RR 1.16 95% CI 1.1–1.3) when compared to patients
with a CRP <11 mg/L measured at index consultation,
but this difference was not statistically significant. Be-
cause patients with higher CRP levels were prescribed
FIGURE 1 Flowchart











antibiotics more often, the observed effect might be
a result of prescription bias. However, antibiotic pre-
scriptions had no significant influence on duration of ill-
ness in this study. Another study, performed in elderly
patients, found that a CRP level of >100 mg/l was an
independent risk factor of mortality within 30 days
(RR 2.5, 95% CI 1.2–5.1). The influence of antibiotics
was not accounted for, while the prevalence of pneu-
monia was relatively high in this population.33
Can CRP predict radiographically confirmed
pneumonia? Study populations differ greatly, the
population used by Melbye et al. showed less signs of
illness than the populations used in the remaining two
studies. The retrieved studies showed different diagnos-
tic properties. Overall, radiographic confirmed pneumo-
nia was present in 13%–17% of patients studied. The
PPV and NPV of CRP, measured in the laboratory,
ranged from 0.17 to 0.42 and from 0.88 to 0.99, respec-
tively. Macfarlane et al. identified an association be-
tween an elevated CRP (>50 mg/l) and radiographic
confirmed pneumonia (OR 5.4, 95% CI 2.7–11.0).
Holm et al.20 found that a CRP level of >20 mg/l was
an independent predictor of pneumonia (OR 2.83, 95%
CI 1.33–6.04). Hopstaken et al.21 evaluated three CRP
cut-off points; 10, 20 and 50 mg/l and found an OR for
pneumonia of 14.1 (95% CI 1.9–105.6), 9.9 (95% CI
2.9–33.7) and 21.4 (95% CI 7.2–63.9), respectively.
Two studies evaluated the diagnostic value of CRP
combined with clinical assessment. Holm et al. com-
bined a CRP of >20 mg/l with a clinical diagnosis of
pneumonia based on history taking and physical exam-
ination, resulting in an OR of 4.97 (95% CI 2.60–9.52).
The PPV and NPV in this case were 0.32 and 0.91,
respectively. These authors also evaluated the use
of either an elevated CRP or a clinical diagnosis of
pneumonia as a predictor of pneumonia. They found
that the PPV was lower (0.20) and the NPV higher
(0.95).20 Hopstaken et al. designed a prediction rule,
using various signs and symptoms combined with
CRP. The performance of this model versus signs
and symptoms alone was shown in receiver operating
characteristic analysis: the area under the curve was
0.9 versus 0.7, respectively.21
Discussion
The studies included in our systematic review showed
limited evidence for the usefulness of rapid POC CRP
measurement in adult patients suspected of LRTI in
primary care. Only one study provided evidence that
a reduction in antibiotic prescriptions may be achieved
when POC CRP measurement is applied.31 Two stud-
ies showed limited value of CRP in diagnosing pneu-
monia, although the diagnostic value increased when
TABLE 1 Validity scorea and relevance of the retrieved articles by research question
Research question Author (year) Validity scorea (%) Relevance
Domain Determinant Outcome





Cals (2009) 56 + + +
Cals (2010) 89 – + +
Diederichsen (2000) 63 – + +
Kavanagh (2011) 17 – + +
Melbye (1995) 86 + + +
Aetiology Adults, LRTI,
primary care
CRP measurement Microbiological diagnosis
Graffelman (2004) 80 + + +
Holm (2007) 91 + + +
Hopstaken (2005) 100 + + +
Macfarlane (2001) 91 + + +
Prognostic value Adults, LRTI,
primary care
CRP measurement Prognosis
Hopstaken (2006) 89 + + +
Melbye (1995) 78 + + +
Seppa (2001) 80 – + +
Diagnostic value Adults, LRTI,
primary care
CRP measurement Radiographic pneumonia
Holm (2007) 83 + + +
Hopstaken (2003) 100 + + +
Macfarlane (2001) 83 + + +
(+), variables used in the article meet the variables aimed for in this review; (–), variables used in the article do not meet the variables aimed for in
this review.
aValidity score: the percentage of (+) scored with the different validated tools.










































X 0.6* (0.5–0.7)* 56










































X 1.0* (0.8–1.2)* 86










>20 UV 4.8 (1.3–18.0) 0.89 0.35 0.49 0.81 80
Throat
swab
MV – – – – –
Serology >50 UV 2.6 (1.0–6.5) 0.66 0.57 0.52 0.70






















>10 UV 1.7 (0.8–3.7) 0.80 0.31 0.23 0.85 100
Nose/throat swab/ >20 UV 1.7 (0.9–3.4) 0.65 0.48 0.25 0.84










































































































>20 UV 5.0 (2.6–9.9) 0.73 0.65 0.24 0.94 83









Infiltrate >10 UV 14.1 (1.9–105.6) 0.97* 0.31* 0.17* 0.99* 100
>20 UV 9.9 (2.9–33.7) 0.91* 0.51* 0.22* 0.97*









Infiltrate >50 UV 5.4 (2.7–11.0)* 0.66* 0.89* 0.42* 0.88* 83
*, calculated; ?, not specified, X, not applicable; NS, not significant; PC, prospective cohort; Sn, sensitivity; Sp, specificity; UV, univariate analysis; MV, multivariate analysis.
a> 18 years of age and cough >4 weeks and physician suspects LRTI and at least one symptom out of the following categories (shortness of breath, wheezing, chest pain, abnormal lung auscultation)
and (fever, perspiration, headache, myalgia, general unwell-being).
b> 18 years of age and LRTI defined as chest infection.
c> 18 years of age and physician suspects pneumonia, bronchitis or asthma and at least one symptom out of the following categories (cough, shortness of breath) or (chest pain which increases by
coughing or deep inspiration).
d> 18 years of age and abnormal lung auscultation and at least two symptom out of the following category [fever (>38C) (reported in the last 48 hours), shortness of breath or cough, tachypnoea or
general unwell-being or confusion).
e> 18 years of age and first consultation with this complaint and physician suspects LRTI.
f> 18 years of age and physician suspects LRTI and new or increasing cough and at least one symptom out of the following categories (shortness of breath, wheezing, chest pain, abnormal lung aus-
cultation) and [(reported) fever (>38C), perspiring, headache, myalgia].
g> 16 years of age and previously well and acute illness (<21 days) and cough is main complaint and LRTI is most likely diagnosis and at least one symptom out of the following category (sputum
production, shortness of breath, wheezing, chest pain/discomfort).
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CRP measurement was combined with clinical assess-
ment.20,21 Patients with pneumonia generally have
a poorer prognosis and their disease is more often
caused by bacteria compared to other forms of LRTI.
It can reasonably be expected that if CRP is an indica-
tor of pneumonia, it would be an indicator of progno-
sis and aetiology as well. Results of the majority of
the retrieved studies do not reflect this association.
CRP cannot be used as a predictor in distinguishing
bacterial from viral aetiology and results on the prog-
nostic value are contradictory. Notably, most studies,
especially those on diagnosis and aetiology, showed
wide CIs which limit the generalizability of findings.
Our review has several strengths and limitations.
We aimed to include all papers that evaluated the
value of CRP measurement in adults with LRTI in pri-
mary care. By defining broadly formulated search syn-
taxes per research question and screening related
articles, citations and references, we attempted to cre-
ate a complete overview of studies on this topic. We
also assessed methodological quality of the included
studies by means of validated instruments. The pre-
ferred association measures were not always provided
in the articles and comparing of data has been made
possible after contacting authors for the crude data.
All studies describe West European patients, allowing
extrapolation of results to European primary care.
However, due to several reasons, results of the dis-
played studies cannot be extrapolated to daily practice
without reservations. Firstly, the golden standards
used in aetiologic and diagnostic studies are of limited
value. In practice, aetiological agents cannot always
be detected, even when sputum cultures, throat swabs
and serological examination are used. In addition,
chest radiographs do not provide absolute diagnostic
certainty, especially in the early stages of pneumonia.
Therefore, the correlations displayed in this review
might be underestimated.
Secondly, in all studies, patient selection bias may
have resulted in incomparable study groups. In four
articles discussing antibiotic prescription, aetiology,
prognosis and/or diagnosis, inclusion and exclusion cri-
teria were poorly defined and inclusion of patients was
largely dependent on the GP’s opinion.20,24,29,33 This
pragmatic study design was possibly chosen in order
to mimic daily practice. Furthermore, in the majority
of studies, characteristics of non-participants were not
provided. Macfarlane et al., however, did report these
characteristics in the study on aetiology and diagnosis.
Non-participants had significantly milder illness
judged from the presence of symptoms like wheezing,
dyspnoea and chest pain.15 As such, the value of CRP
as an indicator of bacterial aetiology and pneumonia
may have been overestimated here. In contrast, in the
study by Holm et al., discussing aetiology and diagno-
sis, characteristics of participants and non-participants
were reported and comparable.20,24
Thirdly, the only study showing a decrease in antibi-
otic prescriptions due to POC CRP measurement
scored relatively low on the Cochrane validity score.31
Because the authors chose to randomize GPs and not
patients, characteristics of the two patient populations
showed important differences. For example, the control
group contained more patients with abnormalities on
chest auscultation, possibly accounting for the higher
prescription rate in these patients. All other studies
showed no differences in antibiotic prescription when
POC CRP tests were used compared to controls.
In the systematic review by van der Meer et al.,10 the
diagnostic value of CRP measurement in LRTI patients
was discussed profoundly. Due to the differences in tar-
get population described in the introduction of this re-
view, only two studies on diagnosing pneumonia were
used in this review as well.21,34 This resulted in a differ-
ent pretest probability of pneumonia and different test
characteristics (sensitivity: this review 66%–97% versus
van der Meer et al. 10%–98%, specificity: this review
31%–89% versus van der Meer et al. 44%–99%). In
contrast to this review, van der Meer did not discuss
the diagnostic value of CRP when combined with signs
and symptoms. Our results suggest that CRP measure-
ment might have an added value in detecting radio-
graphic pneumonia, distinguishing the conclusion by
van der Meer et al.
By issuing the guideline on LRTI, the Dutch Col-
lege of General practitioners places the use of POC
CRP measurement in a practical perspective. In this
guideline, a clinical rule is provided to identify low-
risk patients whom should not receive antibiotics or
a POC CRP test. High-risk patients are identified
based on the GPs professional opinion and should
receive antibiotics or be referred tot the hospital im-
mediately. GPs are advised to use POC CRP measure-
ment only in the remaining patients labelled as ‘patients
at intermediate risk of severe infection’ and prescribe
antibiotics according to test results. However, a different
prevalence of (bacterial) pneumonia can be expected
in this subgroup, thus influencing the pretest probability
and the predictive value of CRP. Until now, studies
that address this subgroup of patients have not been
performed.
Downright introduction of POC CRP measurement
for LRTI patients in primary care might have adverse
effects. Implementation of CRP measurement in
a group largely consisting of low-risk patients leads to
a minimal reduction in antibiotic prescriptions at the
expense of an increase in health care costs.11,12 The es-
timated costs of inappropriate use of POC CRP mea-
surement in Sweden, for example, are as high as e1
million annually.11 The cost-effectiveness of large-
scale implementation of POC CRP in the Netherlands
can be extrapolated from one study performed in our
country. Based on the available evidence, it would
lead to a mean increase of health care costs of e160











per patient.35 However, the number of patients in-
cluded in this study was too small to prove that the
withholding of antibiotics based on POC CRP level
warrants patient safety.
Apart from CRP, other biomarkers used for guiding
diagnosis and treatment in respiratory tract infection
have been evaluated, IL-6 and procalcitonin for exam-
ple.36 Procalcitonin seems the most promising, how-
ever, it cannot be measured in a POC setting yet.
Besides biomarkers, other tools may reduce the
amount of antibiotics prescribed in primary care. For
example, communication skills training may have an
equal effect to POC CRP measurement on the GPs
tendency to prescribe antibiotics, presenting an alter-
native and less costly possibility.31 From this perspec-
tive, POC CRP measurement might not be the most
optimal solution to excessive antibiotic prescription in
LRTI.
In conclusion, judging from the available evidence, the
additional value of implementing POC CRP measure-
ment in the management of LRTI in primary care is lim-
ited. Before implementing POC CRP measurement on
a large scale, as advocated in Dutch guidelines, research
must be done to evaluate the effects and safety of POC
CRP measurement in LRTI patients at intermediate risk
of severe infection.
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TABLE A1 Search syntax per research question
1. Search syntax ‘Antibiotic prescription’
Domain Determinant
Respiratory infection Primary care CRP
Acute cough General practitioner CRP
Acute coughing General practitioners C-reactive protein




Lower respiratory tract General practices
Lower respiratory infection Primary care
Lower respiratory infections Outpatient setting
Respiratory infection Outpatient care
Respiratory infections Family medicine
Respiratory tract infection Primary health care




2. Search syntax ‘Etiology’
Domain Determinant Outcome
Respiratory infection CRP –
Acute cough CRP –
Acute coughing C-reactive protein




Lower respiratory tract Atiologic


















3. Search syntax ‘Prognostic value’
Domain Determinant Outcome
Respiratory infection CRP Prognosis
Acute cough CRP Complication
Acute coughing C-reactive protein Complications




Lower respiratory tract Prognostic
Lower respiratory infection Course






4. Search syntax ‘Diagnostic value’
Domain Determinant Outcome*
Respiratory infection CRP Pneumonia
Acute cough CRP Pneumonia
Acute coughing C-reactive protein CAP











Terms within the columns were connected by ‘or’, and the rows were connected by ‘and’.
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